American Biotech Labs New Wound Care Products Receive Indian Government Approval for Sale

India's Central Drugs Standard Control Organization (CDSCO - equivalent

to FDA in the U.S.) grants approval for the sale of four new

antimicrobial wound care products based on ABL's patented technology;

study results show effectiveness against broad variety of pathogens,

accelerated heal times

Sep 17, 2008, 01:00 ET from Clifton Mining Company

    ALPINE, UT, Sept. 17 /PRNewswire-FirstCall/ - American Biotech Labs
 (ABL), creator of a new class of products based on the company's patented
 nano-catalytic SilverSol Technology(TM), today announced that the agency
 responsible for drug and medical device oversight in India - Central Drugs
 Standard Control Organization ("CDSCO") has approved four new ABL
 antimicrobial wound care products for sale in India. CDSCO is the Indian
 counterpart to the U.S. FDA.
     The four new antimicrobial wound care products are based on ABL's
 patented SilverSol Technology and include: a wound wash; a wound
 disinfectant; an antimicrobial gel; and a patented antimicrobial wound care
     "This approval by India's primary drug and medical device oversight
 organization is a significant milestone for these products and for ABL,"
 said William D. Moeller PhD, Chairman of Clifton Mining Company (OTC: CFTN,
 21-percent owner of ABL). "The approval validates the power and efficacy of
 our technology for wound care. We believe India will be a large market for
 these products."
     "The Indian government has recognized the tremendous potential benefits
 these products can offer in accelerating heal time and reducing cost and
 complications of infection - particularly in health care facilities," said
 Keith Moeller, a Managing Director over sales and marketing for ABL. "We
 are honored to be on the forefront of technology that can provide improved
 healthcare outcomes to people around the globe."
     ABL will market and sell its new product line in India, consistently
 identified as one of the world's largest and most dynamic markets, through
 its partner Viridis Biopharma, headquartered in Mumbai, India. Viridis is a
 supplier of bio-pharma products and medical devices throughout the Indian
     ABL is also currently awaiting 510K regulatory approvals for wound care
 products in the United States and Singapore.
     Separately, recently-completed rigorous efficacy testing of these
 products has shown strong results against a broad variety of resistant
 microbes, including the multi-drug-resistant staph infection MRSA
 (methycillin-resistant staph aureus), VRE (vancomycin-resistant
 enterococci) and numerous other pathogens.
     About American Biotech Labs
     American Biotech Labs (ABL;, founded in
 1998, utilizes patented processes and SilverSol Technology(TM) to create
 singularly powerful and effective nano-catalytic silver products. In
 extensive testing performed by a variety of respected laboratories and
 researchers, ABL's silver hydrosol has consistently demonstrated the
 ability, without any known toxic side effects, to destroy a wide range of
 bacteria, viruses, yeast, and molds. ABL products have been approved by the
 U.S. EPA as a disinfectant for dental water lines, and as a surface
 disinfectant for bacteria, yeast and mold in hospital, residential,
 commercial and industrial settings. The company's products have been the
 subject of a number of peer-reviewed articles in professional journals and
 are sold worldwide at health food stores and by medical professionals under
 the Silver Biotics(R) and ASAP Solution(R) brands, and through a variety of
 private labels.

SOURCE Clifton Mining Company